BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:34 PM
 | 
Jul 10, 2008
 |  BC Extra  |  Company News

CV's ranolazine approved in Europe

EMEA approved an MAA from CV Therapeutics (NASDAQ:CVTX) for ranolazine as add-on therapy to treat patients with stable...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >